#USA #Franklin Lakes #Becton #Dickinson #CVC

BD Unveils Innovative Central Line Insertion Technology: CentroVena One™

On April 29, 2026, BD (Becton, Dickinson and Company), a prominent player in medical technology, announced the launch of the CentroVena One™ Insertion System, a groundbreaking advancement that simplifies the central line placement procedure. This innovative all-in-one central venous catheter (CVC) insertion device is designed specifically for use in acute care settings, focusing on patient safety and procedural efficiency.

A Shift in Central Line Placement Process

The introduction of the CentroVena One™ marks a significant step forward in the methodologies surrounding central line insertion. Ron Silverman, the Executive Vice President and Chief Medical Officer at BD, emphasized this innovation's importance by stating it represents a crucial modification in clinical practices, especially considering the complexity involved in traditional central line placements which often lead to various complications.

Typically, the process of inserting a central line entails multiple steps, contributing significantly to the risk of incorrect insertion and procedural errors. The traditional method has been criticized for being cumbersome, involving many component exchanges, which can delay workflows and compromise patient safety. The CentroVena One™ aims to remedy these issues by consolidating critical components—like the introducer needle, syringe, guidewire, and catheter—into a single, user-friendly system. This all-in-one design not only streamlines the workflow but also enhances safety protocols, significantly minimizing contamination risks during the procedure.

Key Features of CentroVena One™

The new insertion system is engineered to facilitate an intuitive workflow. Here are some of its notable features:

• - Pre-loaded Kink-resistant Guidewire: This component is designed to prevent complications associated with guidewire embolism.
• - Integrated Drape Clip: Permanently attached to the guidewire, this feature helps to further reduce the risk of potential complications during insertion.
• - Self-dilating Catheter Tip: This innovation eliminates the separate dilation step, making the entire process more efficient.
• - Concealed Safety Measures: The introducer needle includes integrated passive safety features that significantly lower the risk of needlestick injuries.
• - Closed Insertion System: Designed to minimize risks related to air embolism, it helps protect both clinicians and patients by reducing blood exposure.

These enhancements align with BD's mission of improving healthcare delivery, as they concentrate on reducing the time traditionally required for central line placements by nearly 50%, which is crucial when patients' lives are at stake.

Early Adoption and Clinical Evaluation

UNC Health Blue Ridge is one of the first health systems to implement this innovative system in clinical settings. According to Dr. Anthony Frank, Chief Medical Officer and Senior Vice President of Medical Affairs, the CentroVena One™ is a game-changer in emergency medicine. It addresses the real-world challenges of central line placement in fast-paced clinical environments, where accuracy and speed are crucial. The design of the product aims to minimize chances of error, maintain sterile environments, and reduce clinicians' workloads, all of which ultimately contribute to patient safety.

Regulatory Approval and Future Implications

The CentroVena One™ Insertion System has received U.S. FDA 510(k) clearance and is part of the FDA's Safer Technologies Program (STeP), which recognizes medical devices that significantly enhance safety in healthcare. BD's dedication to improving vascular access solutions is evident in its continuous commitment to research and innovation, ensuring that they provide high-quality healthcare technology that meets industry challenges.

BD is not only introducing the CentroVena One™ into the acute CVC market; it is also expanding its vascular access product line aimed at minimizing complications arising from traditional central line insertions. This strategic move is aligned with BD's broader goal to enhance patient care experiences across healthcare systems. The CentroVena One™ is now commercially available in the U.S., marking another milestone in BD's endeavor to transform healthcare practices.

For additional details and to explore the product further, visit bd.com/CentroVenaOne. As BD continues to innovate, patients and healthcare providers can look forward to safer, more efficient medical solutions that prioritize public health needs.